A majority of the Supreme Court of the United States' (SCOTUS) justices, both conservative and liberal, did not seem inclined to block the FDA's existing rules for prescribing and dispensing the abortion pill mifepristone.
The case is widely seen as a threat not just to the increased accessibility of abortion pills, but to the FDA's entire structure of regulating pharmaceuticals.
More than half the women in this country who choose to terminate a pregnancy use a combination of pills approved by the FDA, one of which is mifepristone, marketed by Danco Laboratories as Mifeprex.
Please select this link to read the complete article from NPR.